AHR and melanoma: To further investigate the role of the Kyn-AHR pathway in promoting cancer-associated immune suppression in a more controlled setting, we generated a pre-clinical model of B16-F10 melanoma overexpressing IDO (B16IDO) or TDO (B16TDO).